Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study
在EGFR突变型晚期非小细胞肺癌中,疾病进展后继续使用奥希替尼与最佳支持治疗的临床影响:一项多中心回顾性研究
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-15479-w
Oi, Issei; Fujita, Kohei; Imakita, Takuma; Okada, Yuta; Yoshimura, Saiki; Fujimoto, Naoki; Toyama, Shogo; Watanabe, Atsuko; Ito, Takanori; Kaku, Ryosuke; Kanai, Osamu; Ohuchi, Masatsugu; Noguchi, Tetsuo; Tsukino, Mitsuhiro; Sawai, Satoru; Tanizawa, Kiminobu